Business Wire

Microvast Powers the Next Generation of Electric Commercial Vehicles with Groundbreaking Battery Technology at IAA Transportation 2024

16.9.2024 19:11:00 CEST | Business Wire | Press release

Share

Microvast Holdings, Inc. (NASDAQ: MVST) (“Microvast”, the “Company”, “we” or “our”), a technology innovator that designs, develops, and manufactures lithium-ion battery solutions, is advancing the adoption of electric commercial vehicles by launching its latest high-performance battery solutions at IAA Transportation 2024. The new lineup includes the introduction of silicon-based HnSO Cells, Lithium Titanate Oxide (LTO) Cells, and the third-generation MV-I Pack, offering an unprecedented combination of energy density, safety, and sustainability.

Microvast’s advanced battery solutions are designed to meet the rigorous energy demands of commercial transportation, enabling manufacturers to accelerate their shift to cleaner, more efficient electric powertrains.

Technological highlights and new products at IAA Transportation 2024:

  • HnSO Cells (introduction of silicon-based cell technology): With an energy density of 300 Wh/kg, these cells provide high energy density, long cycle life (exceeding 4,000 cycles), and reduced total cost of ownership (TCO), making them ideal for long-range BEV and HEV applications.
  • Lithium Titanate Oxide (LTO) Cells: Known for their enhanced safety and long cycle life of up to 20,000 cycles, LTO cells offer an energy density of 100Wh/kg, optimized for ultra high-power applications in challenging environments.
  • Third Generation MV-I Pack: A robust, lightweight, turn-key solution featuring up to 200 Wh/kg energy density and over 5,000 full cycles. The MV-I Pack also integrates Microvast's 5th generation Battery Management System (BMS), ensuring compliance with ISO 26262 ASIL-C and advanced cybersecurity standards.

Additionally, Microvast introduces our fifth generation Battery Management System (BMS 5.0). BMS 5.0 is engineered for maximum functional safety, adhering to ISO 26262 ASIL-C standards and ISO/SAE 21434:2021 cybersecurity standards. This system ensures the highest levels of safety and security for electric vehicle operations.

Microvast’s latest comprehensive solutions for electric commercial vehicles contain an array of cell, module, and pack solutions, providing a one-stop solution for electric commercial vehicle applications with various operational profiles. With vertical integration from raw materials to turn-key solutions, Microvast offers scalable and versatile products tailored to meet the specific needs of different commercial operations.

Our new battery technology marks a significant advancement for electric commercial vehicles, boasting increased energy density. The rapid charging capabilities facilitate enhanced mobility, while the cycle life is reliably extended. We’re driving the future of electric mobility with solutions that improve efficiency and reduce emissions,” said Dr. Wenjuan Mattis, CTO of Microvast.

Faster innovation, tailored customization, and exceptional quality: the future of e-mobility

Microvast’s vertically integrated model allows for complete control over all phases of development, from R&D to manufacturing. This unique model allows for faster innovation, tailored customization, and exceptional quality, providing commercial vehicle manufacturers with complete, scalable solutions that meet their specific operational needs.

Stefan Herr, Executive Vice President Microvast EMEA, added, “Our innovative battery technology is just the beginning. With a full-service approach, we provide end-to-end solutions for our customers — from tailored energy systems to ongoing support and optimization. We’re committed to delivering not just advanced technology, but a seamless, reliable partnership that ensures maximum performance and long-term success for electric commercial vehicle manufacturers and fleet operators alike.

Reduced carbon emissions as a commitment to sustainability

Microvast’s mission is rooted in sustainability. The company is dedicated to advancing battery technology to accelerate the adoption of electric vehicles, reduce carbon emissions, and contribute to a greener planet. With over 17 years of manufacturing expertise, more than 30,000 installed battery systems worldwide, and a global presence in over 34 countries, Microvast acts as a trusted partner in the global transition to sustainable transportation.

About Microvast

Microvast is a global leader in providing battery technologies for electric vehicles and energy storage solutions. With a legacy of over 17 years, Microvast has consistently delivered cutting-edge battery systems that empower a cleaner and more sustainable future. The Company's innovative approach and dedication to excellence have positioned it as a trusted partner for customers around the world. Microvast was founded in 2006 and is headquartered in Stafford, Texas.

For more information, please visit www.microvast.com or follow us on LinkedIn (@microvast).

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results; our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook,” or words of similar meaning. These forward-looking statements include, but are not limited to, statements regarding Microvast’s industry and market sizes, future opportunities for Microvast, and Microvast’s estimated future results. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic, and competitive uncertainties, and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240915144080/en/

Contacts

Investor Relations Contact

Investor Relations Contact
ir@microvast.com

ir@microvast.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye